Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma-论文-万方医学网

Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma

导出原文传递

翻译打印收藏纠错

作者： Ishiyama, Yudai ^[1] ; Kondo, Tsunenori ^[2] ; Nemoto, Yuki ; Kobari, Yuki ; Ishihara, Hiroki ; Tachibana, Hidekazu ; Yoshida, Kazuhiko ; Hashimoto, Yasunobu ; Takagi, Toshio ; Iizuka, Junpei ; Tanabe, Kazunari

作者单位： Dept Urol,Tokyo Womens Med Univ ^[1] Dept Urol,Saiseikai Kawaguchi Gen Hosp ^[2]

关键词 Antibiotics Gut microbiota Immunotherapy Pembrolizumab Urothelial carcinoma URINARY-TRACT-INFECTIONS CANCER ATEZOLIZUMAB MULTICENTER MICROBIOME GUIDELINE CISPLATIN THERAPY TUMOR

发布时间 2024-04-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma

相似文献

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma

相似文献

相关期刊

检索历史清除